Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Denali Therapeutics Inc (DNLI)

Denali Therapeutics Inc (DNLI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Denali Therapeutics Inc 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 USA

P: 650-866-8548

Description:

Denali Therapeutics, a biopharmaceutical company, is developing a wide and innovative portfolio of targeted therapeutic candidates, which are engineered to cross the blood-brain barrier for neurodegenerative diseases. It has 5 clinical-stage programs, a leucine-rich repeat kinase 2 inhibitor program partnered with Biogen to address Parkinson's disease, an eukaryotic translation initiation factor 2B activator program to address diseases such as amyotrophic lateral sclerosis and frontotemporal dementia (FTD), the ETV:IDS program, which utilizes the company's enzyme transport vehicle technology, and is designed to restore iduronate 2-sulfatase and reduce glycosaminoglycans, in patients with mucopolysaccharidosis II, and two separate receptor interacting serine/threonine protein kinase 1 inhibitor programs, both partnered with Sanofi. It also has a collaboration and option agreement with Takeda Pharmaceutical Co. Ltd. Takeda has exercised its option to jointly develop and commercialize DNL593 with the company.

Key Statistics

Overview:

Market Capitalization, $K 4,098,867
Enterprise Value, $K 3,233,457
Shares Outstanding, K 135,814
Annual Sales, $ 48,660 K
Annual Net Income, $ -290,580 K
Last Quarter Sales, $ 3,560 K
Last Quarter Net Income, $ -103,300 K
60-Month Beta 1.46
% of Insider Shareholders 12.70%
% of Institutional Shareholders 74.56%
Float, K 118,566
% Float 87.30%
Short Volume Ratio 0.36

Growth:

1-Year Return -30.40%
3-Year Return 65.28%
5-Year Return 40.70%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.84 on 11/03/22
Next Earnings Date N/A
Earnings Per Share ttm -2.47
EPS Growth vs. Prev Qtr -75.00%
EPS Growth vs. Prev Year -21.74%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

DNLI Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -33.85%
Return-on-Assets % -23.07%
Profit Margin % -597.16
Net Margin % N/A
Debt/Equity 0.00
Price/Sales 80.47
Price/Cash Flow N/A
Price/Book 4.83
Book Value/Share 5.97
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar